Led by emerging biotech companies, the American Biotech Innovation Alliance strengthens American leadership in science and technology to fuel the innovation pipeline, driving tomorrow’s cures.
Learn more
America leads the world in biotech discovery, but the foundations of that leadership are increasingly strained. Critical components of the innovation pipeline—from R&D investment to manufacturing to workforce—are moving offshore or facing capacity constraints at home. And with small- and mid-sized companies now driving most new drug approvals, the U.S. must strengthen the ecosystem that supports their path from discovery to scale.
The numbers reveal the pressure points:
U.S. biopharma R&D investment accounts for 55% of the global total, but competitors are rapidly narrowing the gap1
China controls 80% of global production for active pharmaceutical ingredients (APIs) used in antibiotics and other key compounds2
U.S. biopharmaceutical companies offshore 30% of FDA-approved drug workflows to Chinese contract development and manufacturing organizations (CDMOs)3
Small and mid-sized companies accounted for ~72% of the FDA’s novel drug approvals in 20244
Vision 2030: A National Innovation Plan for American Biotech
Establish the unique identity of the biotech industry
bolster early stage research and develop the next generation of talent
Advocate for a modern, flexible regulatory environment
Stimulate and support patient-centric scientific innovation and treatment delivery
This is a time-limited opportunity for visionary organizations and leaders to shape America’s biotech future. Founding Fifty members will:
Secure the future of American biotech innovation.
Join the Founding Fifty